Please assess the completion status of the following clinical trial:

Trial Title: A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Aged 18-75 years~Histologically or cytologically confirmed extensive-stage disease small cell lung cancer (ED SCLC)~Ongoing clinical benefit (partial response \[PR\], or complete response \[CR\] per RECIST version 1.1) following completion of 4 cycles of first-line platinum-based therapy (cisplatin or carboplatin, plus etoposide)~Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~Subjects must have adequate bone marrow, renal and hepatic function~Exclusion Criteria:~Subjects with Central Nervous System (CNS) metastases~Subjects receiving consolidative chest radiation after last dose of first-line chemotherapy.~Subjects with pleural effusions that cannot be controlled with appropriate interventions.~All side effects attributed to prior anti-cancer therapy must have resolved to Grade 1 or baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ZL-2306(nirapairb) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).